Exubera's Problem: It's Still Just Insulin
Executive Summary
Exubera's shaky start isn't that surprising. Pfizer is new to the large molecule game, Exubera's a first of its kind, and, it seems, injections aren't so much the problem as insulin itself.
You may also be interested in...
Oral Molecules In An Injectable World: What Developers Need To Do Now
Companies developing new orally delivered molecules for specialty markets must position their drugs as more than just convenient alternatives to injectable therapies.
Oral Molecules In An Injectable World: What Developers Need To Do Now
Companies developing new orally delivered molecules for specialty markets must position their drugs as more than just convenient alternatives to injectable therapies.
Blow the Launch -- Doom the Product
A new IMS survey shows that payors are now virtually the most important determinant of marketplace success -- far more important, in most markets, including the US, than sales representatives, who are less influential than they have ever been. Moreover, marketers who can't create a strong market penetration within six months of launch, will almost certainly fail - no matter what they do - to be able to improve the sales curve.